drugset / Trial / NCT05142488
Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine
Phase 4
Unknown
662 enrolled
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to evaluate the antibody response, safety and reactogenicity of a third dose Covid-19 (recombinante) vaccine, 6 months after a two-dose vaccine schedule using the same vaccine in all doses.
Timeline
- Start
- 2021-11-09
- Primary completion
- 2022-03-30
- Completion
- 2023-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Covid-19 (recombinante) vaccine | Vaccine | — | — |